Hans Schikan is former Chief Executive Officer of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) since June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Before joining Prosensa, Hans worked at Genzyme, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he worked at Organon, both at corporate level and in country operations which included assignments in Asia and Europe.
Hans has recently been appointed to Chairman of the Board for two European Biotechs; InteRNA and Asceneuron. InteRNA is a Netherlands company working in the area of miRNA. Asceneuron, a company spun out of Merck Serono, is an emerging leader in the development of innovative small molecules targeting tauopathies such as progressive supranuclear palsy (PSP), Alzheimer’s disease and related neurodegenerative diseases.
Schikan was recently appointed to the Chairman role of Complix and also sits on the board at SOBI.